BALVERSA Adoption On The Rise: Meeting Unmet Needs In Advanced Urothelial Cancer | Delveinsight
BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, particularly as a targeted therapy for patients wi ...
Pharm Exec3h
FDA Approves BeiGene’s Tevimbra for Unresectable or Metastatic Esophageal Squamous Cell Carcinoma
New indication for Tevimbra in combination with platinum-containing chemotherapy as a first-line treatment addresses an unmet ...
centerforbiosimilars4h
FDA Approves Third Pair of Denosumab Biosimilars
The approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a biosimilar to treat ...
Pharm Exec5h
FDA Approves Celltrion’s Biosimilars Stoboclo and Osenvelt
Stoboclo, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Osenvelt, a ...
Parade on MSN5h
Ben Stiller Fans Dub Him a ‘Legend’ for His Response to Sick Fan’s Bucket List Request
Ben Stiller has earned the status of "legend" from fans after replying to a sick fan's request to help her check an item off ...
The American Journal of Managed Care7h
First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1
Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...